GlassScriptPhysician profile
Morris R Hamilton
NPI 1649240599
$6,158.14
in general payments reported to CMS, 2019-2025
25 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $309 · 2021: $770 · 2022: $1,284 · 2023: $1,195 · 2024: $1,144 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,135 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,134.61 |
| Education | $210.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $950.21 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $893.26 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $580.76 | 2019-2025 | Jynarque |
| Akebia Therapeutics INC | $554.93 | 2019-2024 | Auryxia, Vafseo |
| Vifor Pharma, INC. | $458.03 | 2019-2023 | Korsuva, Veltassa |
| Amgen INC. | $394.64 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Mallinckrodt Hospital Products INC. | $375.51 | 2020-2025 | Acthar |
| Opko Pharmaceuticals, LLC | $304.01 | 2020-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $250.59 | 2023-2025 | |
| Travere Therapeutics, INC. | $231.14 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $159.24 | 2022-2025 | Purified Cortrophin Gel |
| Daiichi Sankyo INC. | $139.44 | 2020-2025 | Injectafer |
| Aurinia Pharma U.S., INC. | $133.33 | 2022-2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.26 | 2024-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $110.34 | 2019-2025 | Velphoro |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $96.10 | 2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $78.70 | 2022-2025 | Shingrix, Arexvy |
| Ardelyx, INC. | $77.27 | 2024-2025 | Ibsrela |
| Nxstage Medical, INC. | $69.90 | 2021 | |
| Mallinckrodt Enterprises LLC | $62.82 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $25.00 | 2022 | |
| Renalytix Ai, INC. | $23.99 | 2022 | |
| Genentech USA, INC. | $21.34 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.63 | 2019 | |
| Apellis Pharmaceuticals, INC. | $18.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morris Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.